87S.F - Roivant Sciences Ltd.

Frankfurt - Frankfurt Delayed price. Currency in EUR

Roivant Sciences Ltd.

50 Broadway
7th Floor
London SW1H 0DB
United Kingdom
44 20 7400 3347

Full-time employees863

Key executives

NameTitlePayExercisedYear born
Mr. Matthew GlineCEO & Director1.45MN/A1984
Dr. Eric Venker M.D., Pharm.D.Pres & COO981.38kN/A1987
Dr. Mayukh Sukhatme M.D.Pres & Chief Investment Officer910.19kN/A1976
Mr. Richard PulikChief Financial OfficerN/AN/A1980
Ms. Rakhi KumarChief Accounting OfficerN/AN/A1980
Dr. Huafeng Xu Ph.D.Chief Technology OfficerN/AN/AN/A
Mr. Josh ChenGen. CounselN/AN/AN/A
Ms. Kelly GraffHead of PeopleN/AN/AN/A
Ms. Marianne L. RomeoHead of Global Transactions & Risk ManagementN/AN/A1968
Mr. Alex GasnerExec. VP of Roivant HealthN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Roivant Sciences Ltd. focuses on discovery, development, and commercialization of medicines. It develops transformative medicines by building technologies and developing talent in creative ways, leveraging its platform to launch Vants – nimble and focuses biopharmaceutical and health technology companies. The company was founded in 2014 and is based in London, the United Kingdom.

Corporate governance

Roivant Sciences Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.